Open Access Review Article Article ID: JCMC-7-237

    Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in an outbreak of SARS-CoV-2

    Didar Yanardag Acik*

    In COVID-19, hypertension, diabetes mellitus, coronary artery disease, and immunosuppression are comorbid conditions most often associated with poor prognosis. Angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers are widely used in the treatment of these diseases. Therefore, scientists turned their attention to these drugs and brought up the question of whether angiotensin converting enzyme inhibitors and angiotensin receptor blockers may be drugs that adversely affect prognosis in SARS-CoV-2 infection. The authors generally discussed the role of these drugs in SARS-CoV-2 infection through the same mechanisms. We also investigated the effects of these drugs on the immune system.


    Published on: Jun 11, 2020 Pages: 200-203

    Full Text PDF Full Text HTML DOI: 10.17352/2455-2976.000137
    Get Citation Base Search Scilit OAI-PMH ResearchGate GrowKudos CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on JCMC